Why open clinical-trial data alone is not enough
Open registries are valuable, but raw listing volume alone does not produce clinical priority.
The practical physician question is not “how many records exist?” but “which options are most relevant for this case now?”.
Value emerges not from data access itself, but from ranking tied to tumor type, biomarker profile, stage, and treatment line.
Final eligibility still depends on protocol-level and site-level review.
Next step
Zynova OncoAtlas supports oncology workflow, evidence navigation, and clinical documentation. It does not diagnose, prescribe treatment, or replace licensed physicians.